October 15, 2013

Johnson & Johnson Reports 2013 Third-Quarter Results:

Sales of $17.6 Billion increased 3.1% Versus 2012 Third Quarter;
Third-Quarter EPS was $1.04
Excluding Special Items, 2013 Third-Quarter EPS of $1.36 increased 8.8%*

NEW BRUNSWICK, N.J., Oct. 15, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.6 billion for the third quarter of 2013, an increase of 3.1% as compared to the third quarter of 2012. Operational results increased 4.7% and the negative impact of currency was 1.6%. Domestic sales increased 1.7%.  International sales increased 4.2%, reflecting operational growth of 7.1% and a negative currency impact of 2.9%.

Net earnings ** and diluted earnings per share for the third quarter of 2013 were $3.0 billion and $1.04, respectively. The third quarter results included after-tax special items of approximately $0.9 billion, primarily related to an increase in the accrual for litigation expenses, in-process research and development expense, and integration and transaction costs related to the acquisition of Synthes, Inc.  Third quarter 2012 net earnings included after-tax special items of approximately $0.6 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $3.9 billion and diluted earnings per share were $1.36, representing increases of 11.3% and 8.8%, respectively, as compared to the same period in 2012.*  

"Our third-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers," said Alex Gorsky, Chairman and Chief Executive Officer. "Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations. Our investments further strengthen our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers."

The Company increased its earnings guidance for full-year 2013 to $5.44 - $5.49 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.6 billion for the third quarter represented an increase of 0.8% versus the prior year consisting of an operational increase of 2.0% and a negative impact from currency of 1.2%.  Domestic sales increased 0.9%. International sales increased 0.8%, which reflected an operational increase of 2.6% and a negative currency impact of 1.8%.

Positive contributors to operational results were U.S. sales of TYLENOL® and MOTRIN® analgesics; upper respiratory over the counter medicines; AVEENO® skin care products and international baby care products.

Worldwide Pharmaceutical sales of $7.0 billion for the third quarter represented an increase of 9.9% versus the prior year with operational growth of 10.9% and a negative impact from currency of 1.0%.  Domestic sales increased 7.9%. International sales increased 12.0% which reflected an operational increase of 14.0% and a negative currency impact of 2.0%. 

Primary contributors to operational sales growth were INVEGA®  SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; REMICADE® (infliximab) and SIMPONI® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; VELCADE® (bortezomib), a treatment for multiple myeloma; PREZISTA® (darunavir), a treatment for HIV; and sales of new products.

The strong sales results of new products include ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; and INVOKANA® (canagliflozin) for the treatment of adults with type 2 diabetes.

During the quarter, the European Commission approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who had an inadequate response to conventional therapy. In addition, the European Commission approved the use of VELCADE® (bortezomib) as induction therapy in combination with dexamethasone or thalidomide and dexamethasone and applies to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with hematological stem cell transplantation.

Also, during the quarter, the European Commission approved STELARA® (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate, and the U.S. Food and Drug Administration (FDA) approved STELARA®  alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. Additionally, the FDA approved SIMPONI® ARIA™ (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

In September, the Committee for Medical Products for Human Use of The European Medicines Agency granted a positive opinion recommending approval of INVOKANA® (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycemic control. 

In October, we announced the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. We acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs.

Worldwide Medical Devices and Diagnostics sales of $6.9 billion for the third quarter represented a decrease of 2.0% versus the prior year consisting of an operational increase of 0.3% and a negative currency impact of 2.3%. Domestic sales decreased 4.2%. International sales decreased 0.1%, which reflected an operational increase of 4.2% and a negative currency impact of 4.3%.

Primary contributors to operational growth were sales from Biosense Webster's electrophysiology products in the Cardiovascular Care business; joint reconstruction products in the Orthopaedics business; international sales in the Surgical Care business; and biosurgical and international sales of energy products in the Specialty Surgery business.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,700 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings ** and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

** Net earnings attributable to Johnson & Johnson.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS
(This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; the effects of a continued federal government shutdown including the FDA's ability to take new regulatory submissions and continue review of our existing submissions without delays; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


Johnson & Johnson and Subsidiaries

















Supplementary Sales Data



















(Unaudited; Dollars in Millions)



THIRD QUARTER








NINE MONTHS









Percent Change






Percent Change



2013


2012


Total


Operations


Currency


2013


2012


Total


Operations


Currency

Sales to customers by

segment of business





























































Consumer





















  U.S.

$

1,225


1,214


0.9

%

0.9


-

$

3,899


3,843


1.5

%

1.5


-

    International


2,386


2,367


0.8


2.6


(1.8)


7,045


6,952


1.3


2.7


(1.4)



3,611


3,581


0.8


2.0


(1.2)


10,944


10,795


1.4


2.3


(0.9)






















Pharmaceutical





















    U.S.


3,549


3,288


7.9


7.9


-


10,397


9,408


10.5


10.5


-

    International


3,487


3,114


12.0


14.0


(2.0)


10,432


9,418


10.8


12.9


(2.1)



7,036


6,402


9.9


10.9


(1.0)


20,829


18,826


10.6


11.7


(1.1)






















Med Devices & Diagnostics





















    U.S.


3,151


3,289


(4.2)


(4.2)


-


9,600


9,119


5.3


5.3


-

    International


3,777


3,780


(0.1)


4.2


(4.3)


11,584


10,926


6.0


10.0


(4.0)



6,928


7,069


(2.0)


0.3


(2.3)


21,184


20,045


5.7


7.9


(2.2)






















U.S.


7,925


7,791


1.7


1.7


-


23,896


22,370


6.8


6.8


-

International


9,650


9,261


4.2


7.1


(2.9)


29,061


27,296


6.5


9.2


(2.7)

Worldwide

$

17,575


17,052


3.1

%

4.7


(1.6)

$

52,957


49,666


6.6

%

8.1


(1.5)

 

Johnson & Johnson and Subsidiaries

















Supplementary Sales Data




















(Unaudited; Dollars in Millions)



THIRD QUARTER








NINE MONTHS









Percent Change






Percent Change



2013


2012


Total


Operations


Currency


2013


2012


Total


Operations


Currency

Sales to customers by

geographic area





























































U.S.

$

7,925


7,791


1.7

%

1.7


-

$

23,896


22,370


6.8

%

6.8


-






















Europe


4,478


3,983


12.4


8.4


4.0


13,631


12,342


10.4


8.6


1.8

Western Hemisphere excluding U.S.


1,842


1,824


1.0


8.0


(7.0)


5,530


5,266


5.0


10.3


(5.3)

Asia-Pacific, Africa


3,330


3,454


(3.6)


5.1


(8.7)


9,900


9,688


2.2


9.2


(7.0)

International


9,650


9,261


4.2


7.1


(2.9)


29,061


27,296


6.5


9.2


(2.7)






















Worldwide

$

17,575


$17,052


3.1

%

4.7


(1.6)

$

52,957


$49,666


6.6

%

8.1


(1.5)

 

Johnson & Johnson and Subsidiaries









Condensed Consolidated Statement of Earnings 








(Unaudited; in Millions Except Per Share Figures)

THIRD QUARTER
















2013


2012


Percent





Percent




Percent


Increase



Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$

17,575


100.0

$

17,052


100.0


3.1

Cost of products sold


5,344


30.4


5,597


32.8


(4.5)

Selling, marketing and administrative expenses


5,314


30.2


5,228


30.6


1.6

Research and development expense


2,042


11.6


1,923


11.3


6.2

In-process research and development


178


1.0


679


4.0



Interest (income) expense, net


87


0.5


120


0.7



Other (income) expense, net


943


5.4


(90)


(0.5)



Earnings before provision for taxes on income


3,667


20.9


3,595


21.1


2.0

Provision for taxes on income


685


3.9


966


5.7


(29.1)

Net earnings


2,982


17.0


2,629


15.4


13.4

Add: Net loss attributable to noncontrolling interest


-


-


339


2.0



Net earnings attributable to Johnson & Johnson

$

2,982


17.0

$

2,968


17.4


0.5












Net earnings per share attributable to Johnson & Johnson (Diluted)

$

1.04




1.05




(1.0)












Average shares outstanding (Diluted)


2,881.2




2,818.1
















Effective tax rate


18.7

%



26.9

%















Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)







Earnings before provision for taxes on income

$

4,831


27.5

$

4,525


26.5


6.8

Net earnings attributable to Johnson & Johnson

$

3,919


22.3

$

3,521


20.6


11.3

Net earnings per share attributable to Johnson & Johnson (Diluted)

$

1.36



$

1.25




8.8

Effective tax rate


18.9

%



22.2

%















(1) See Reconciliation of Non-GAAP Financial Measures.











 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings










(Unaudited; in Millions Except Per Share Figures)





NINE MONTHS
















2013


2012


Percent





Percent to




Percent to


Increase



Amount


Sales


Amount


Sales


(Decrease)

Sales to customers

$

52,957


100.0

$

49,666


100.0


6.6

Cost of products sold


16,387


30.9


15,655


31.5


4.7

Selling, marketing and administrative expenses


15,913


30.0


15,208


30.6


4.6

Research and development expense


5,772


10.9


5,334


10.7


8.2

In-process research and development


242


0.5


1,108


2.2



Interest (income) expense, net


292


0.6


379


0.8



Other (income) expense, net


1,630


3.1


1,307


2.7



Earnings before provision for taxes on income


12,721


24.0


10,675


21.5


19.2

Provision for taxes on income


2,409


4.5


2,728


5.5


(11.7)

Net earnings


10,312


19.5


7,947


16.0


29.8

Add: Net loss attributable to noncontrolling interest


-


-


339


0.7



Net earnings attributable to Johnson & Johnson

$

10,312


19.5

$

8,286


16.7


24.5












Net earnings per share attributable to Johnson & Johnson (Diluted)

$

3.58



$

2.96




20.9












Average shares outstanding (Diluted)


2,879.0




2,805.0
















Effective tax rate


18.9

%



25.6

%















Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)







Earnings before provision for taxes on income

$

15,260


28.8

$

14,099


28.4


8.2

Net earnings attributable to Johnson & Johnson

$

12,315


23.3

$

10,969


22.1


12.3

Net earnings per share attributable to Johnson & Johnson (Diluted)

$

4.28



$

3.91




9.5

Effective tax rate


19.3

%



22.2

%















(1) See Reconciliation of Non-GAAP Financial Measures.











 

Johnson & Johnson and Subsidiaries












Reconciliation of Non-GAAP Financial Measures




























Third Quarter


% Incr. /


Nine Months YTD


% Incr. /

(Dollars in Millions Except Per Share Data)


2013


2012


(Decr.)


2013


2012


(Decr.)
















Earnings before provision for taxes on income - as reported

$

3,667


3,595


2.0

%

$

12,721

$

10,675


19.2

%
















Litigation expenses


872


89





1,776


758



















In-process research and development


178


679





242


1,108



















Synthes integration/transaction costs and currency related


122


165

(1)




502


622



















DePuy ASR™Hip program


35


27





117


27



















Intangible asset write-downs


-


-





-


939



















Other


(43)


(30)





(98)


(30)



















Earnings before provision for taxes on income - as adjusted

$

4,831


4,525


6.8

%

$

15,260


14,099


8.2

%
















Net Earnings attributable to Johnson & Johnson - as reported

$

2,982


2,968


0.5

%

$

10,312


8,286


24.5

%
















Litigation expenses


720


70





1,419


681



















In-process research and development


126


340

(2)




168


684



















Synthes integration/transaction costs and currency related


103


135





373


593



















DePuy ASR™ Hip program


31


24





122


24



















Intangible asset write-downs


-


-





-


717



















Other


(43)


(16)





(79)


(16)



















Net Earnings attributable to Johnson & Johnson - as adjusted 

$

3,919


3,521


11.3

%

$

12,315


10,969


12.3

%
















Diluted Net Earnings per share attributable to Johnson & Johnson - as reported

$

1.04


1.05


(1.0)

%

$

3.58


2.96


20.9

%
















Litigation expenses


0.25


0.02





0.49


0.24



















In-process research and development


0.04


0.13





0.06


0.24



















Synthes integration/transaction costs and currency related


0.04


0.05





0.13


0.21



















DePuy ASR™ Hip program


0.01


0.01





0.04


0.01



















Intangible asset write-downs


-


-





-


0.26



















Other


(0.02)


(0.01)





(0.02)


(0.01)



















Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted 

$

1.36


1.25


8.8

%

$

4.28


3.91


9.5

%































(1) Represents inventory step-up recorded in cost of products sold






























(2) In-process research and development of $679M offset by $339M reported as net loss attributable to noncontrolling interest

























The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.




 


REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational(1)

Currency

CONSUMER SEGMENT (2) (4)
















BABY CARE
















US

$

99


104

-4.8%

-4.8%

-


$

308


309

-0.3%

-0.3%

-

Intl


461


460

0.2%

4.3%

-4.1%



1,402


1,373

2.1%

5.2%

-3.1%

WW


560


564

-0.7%

2.6%

-3.3%



1,710


1,682

1.7%

4.2%

-2.5%

ORAL CARE
















US


142


162

-12.3%

-12.3%

-



449


476

-5.7%

-5.7%

-

Intl


253


251

0.8%

3.2%

-2.4%



755


732

3.1%

4.8%

-1.7%

WW


395


413

-4.4%

-3.0%

-1.4%



1,204


1,208

-0.3%

0.8%

-1.1%

OTC (3)
















US


310


263

17.9%

17.9%

-



954


801

19.1%

19.1%

-

Intl


665


653

1.8%

2.0%

-0.2%



1,995


1,949

2.4%

2.7%

-0.3%

WW


975


916

6.4%

6.5%

-0.1%



2,949


2,750

7.2%

7.4%

-0.2%

SKIN CARE
















US


404


390

3.6%

3.6%

-



1,320


1,314

0.5%

0.5%

-

Intl


520


514

1.2%

2.1%

-0.9%



1,414


1,410

0.3%

0.9%

-0.6%

WW


924


904

2.2%

2.7%

-0.5%



2,734


2,724

0.4%

0.7%

-0.3%

WOMEN'S HEALTH
















US


77


81

-4.9%

-4.9%

-



242


254

-4.7%

-4.7%

-

Intl


331


326

1.5%

4.3%

-2.8%



978


964

1.5%

4.2%

-2.7%

WW


408


407

0.2%

2.5%

-2.3%



1,220


1,218

0.2%

2.4%

-2.2%

WOUND CARE/OTHER (3)
















US


193


214

-9.8%

-9.8%

-



626


689

-9.1%

-9.1%

-

Intl


156


163

-4.3%

-3.0%

-1.3%



501


524

-4.4%

-3.8%

-0.6%

WW


349


377

-7.4%

-6.9%

-0.5%



1,127


1,213

-7.1%

-6.8%

-0.3%

















TOTAL CONSUMER
















US


1,225


1,214

0.9%

0.9%

-



3,899


3,843

1.5%

1.5%

-

Intl


2,386


2,367

0.8%

2.6%

-1.8%



7,045


6,952

1.3%

2.7%

-1.4%

WW

$

3,611


3,581

0.8%

2.0%

-1.2%


$

10,944


10,795

1.4%

2.3%

-0.9%

















 

See footnotes at end of schedule














 


REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (4)
















IMMUNOLOGY
















US

$

1,648


1,600

3.0%

3.0%

-


$

4,865


4,524

7.5%

7.5%

-

Intl


695


484

43.6%

47.7%

-4.1%



1,923


1,374

40.0%

43.3%

-3.3%

WW


2,343


2,084

12.4%

13.4%

-1.0%



6,788


5,898

15.1%

15.9%

-0.8%

REMICADE
















US 


1,013


940

7.8%

7.8%

-



2,909


2,712

7.3%

7.3%

-

US Exports (5)


291


379

-23.2%

-23.2%

-



972


1,123

-13.4%

-13.4%

-

Intl


385


272

41.5%

46.1%

-4.6%



1,080


800

35.0%

38.2%

-3.2%

WW


1,689


1,591

6.2%

7.0%

-0.8%



4,961


4,635

7.0%

7.5%

-0.5%

SIMPONI
















US


111


93

19.4%

19.4%

-



292


220

32.7%

32.7%

-

Intl


155


92

68.5%

74.9%

-6.4%



386


206

87.4%

95.3%

-7.9%

WW


266


185

43.8%

47.0%

-3.2%



678


426

59.2%

63.0%

-3.8%

STELARA
















US


233


188

23.9%

23.9%

-



692


469

47.5%

47.5%

-

Intl


137


99

38.4%

38.6%

-0.2%



395


287

37.6%

38.5%

-0.9%

WW


370


287

28.9%

29.0%

-0.1%



1,087


756

43.8%

44.1%

-0.3%

OTHER IMMUNOLOGY
















US


-


-

-

-

-



-


-

-

-

-

Intl


18


21

-14.3%

-8.1%

-6.2%



62


81

-23.5%

-21.4%

-2.1%

WW


18


21

-14.3%

-8.1%

-6.2%



62


81

-23.5%

-21.4%

-2.1%

INFECTIOUS DISEASES
















US


278


259

7.3%

7.3%

-



775


738

5.0%

5.0%

-

Intl


543


536

1.3%

-0.1%

1.4%



1,831


1,600

14.4%

14.7%

-0.3%

WW


821


795

3.3%

2.4%

0.9%



2,606


2,338

11.5%

11.7%

-0.2%

INCIVO
















US


-


-

-

-

-



-


-

-

-

-

Intl


76


71

7.0%

5.3%

1.7%



410


305

34.4%

36.1%

-1.7%

WW


76


71

7.0%

5.3%

1.7%



410


305

34.4%

36.1%

-1.7%

INTELENCE
















US


47


45

4.4%

4.4%

-



138


130

6.2%

6.2%

-

Intl


45


49

-8.2%

-9.2%

1.0%



146


135

8.1%

8.1%

0.0%

WW


92


94

-2.1%

-2.6%

0.5%



284


265

7.2%

7.2%

0.0%

PREZISTA
















US


215


181

18.8%

18.8%

-



578


507

14.0%

14.0%

-

Intl


195


183

6.6%

4.4%

2.2%



634


554

14.4%

14.0%

0.4%

WW


410


364

12.6%

11.5%

1.1%



1,212


1,061

14.2%

14.0%

0.2%

OTHER INFECTIOUS DISEASES
















US


16


33

-51.5%

-51.5%

-



59


101

-41.6%

-41.6%

-

Intl


227


233

-2.6%

-3.4%

0.8%



641


606

5.8%

6.0%

-0.2%

WW


243


266

-8.6%

-9.3%

0.7%



700


707

-1.0%

-0.8%

-0.2%

















 


REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

















NEUROSCIENCE
















US


601


678

-11.4%

-11.4%

-



1,973


2,010

-1.8%

-1.8%

-

Intl


991


990

0.1%

4.6%

-4.5%



3,043


3,019

0.8%

4.6%

-3.8%

WW


1,592


1,668

-4.6%

-1.9%

-2.7%



5,016


5,029

-0.3%

2.0%

-2.3%

CONCERTA/METHYLPHENIDATE
















US


38


150

-74.7%

-74.7%

-



262


493

-46.9%

-46.9%

-

Intl


104


104

0.0%

3.5%

-3.5%



351


337

4.2%

6.6%

-2.4%

WW


142


254

-44.1%

-42.7%

-1.4%



613


830

-26.1%

-25.1%

-1.0%

INVEGA
















US


82


78

5.1%

5.1%

-



229


223

2.7%

2.7%

-

Intl


65


62

4.8%

11.0%

-6.2%



200


180

11.1%

16.9%

-5.8%

WW


147


140

5.0%

7.8%

-2.8%



429


403

6.5%

9.1%

-2.6%

INVEGA SUSTENNA/ XEPLION
















US


180


130

38.5%

38.5%

-



502


350

43.4%

43.4%

-

Intl


144


82

75.6%

72.9%

2.7%



396


218

81.7%

80.1%

1.6%

WW


324


212

52.8%

51.7%

1.1%



898


568

58.1%

57.5%

0.6%

RISPERDAL CONSTA
















US


114


113

0.9%

0.9%

-



327


336

-2.7%

-2.7%

-

Intl


212


238

-10.9%

-8.7%

-2.2%



670


731

-8.3%

-6.1%

-2.2%

WW


326


351

-7.1%

-5.6%

-1.5%



997


1,067

-6.6%

-5.1%

-1.5%

OTHER NEUROSCIENCE
















US


187


207

-9.7%

-9.7%

-



653


608

7.4%

7.4%

-

Intl


466


504

-7.5%

-0.7%

-6.8%



1,426


1,553

-8.2%

-2.8%

-5.4%

WW


653


711

-8.2%

-3.4%

-4.8%



2,079


2,161

-3.8%

0.1%

-3.9%

ONCOLOGY
















US


227


145

56.6%

56.6%

-



632


371

70.4%

70.4%

-

Intl


754


483

56.1%

57.1%

-1.0%



2,028


1,439

40.9%

42.9%

-2.0%

WW


981


628

56.2%

57.0%

-0.8%



2,660


1,810

47.0%

48.6%

-1.6%

VELCADE
















US


-


-

-

-

-



-


-

-

-

-

Intl


404


327

23.5%

26.3%

-2.8%



1,136


998

13.8%

16.7%

-2.9%

WW


404


327

23.5%

26.3%

-2.8%



1,136


998

13.8%

16.7%

-2.9%

ZYTIGA
















US


204


136

50.0%

50.0%

-



539


349

54.4%

54.4%

-

Intl


260


129

*

97.1%

4.5%



664


348

90.8%

89.1%

1.7%

WW


464


265

75.1%

72.9%

2.2%



1,203


697

72.6%

71.7%

0.9%

OTHER ONCOLOGY
















US


23


9

*

*

-



93


22

*

*

-

Intl


90


27

*

*

-5.2%



228


93

*

*

-5.7%

WW


113


36

*

*

-3.8%



321


115

*

*

-4.6%

















 


REPORTED SALES vs. PRIOR PERIOD ($MM)



THIRD QUARTER


NINE MONTHS







% Change






% Change




2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency


TOTAL OTHER

















US


795


606

31.2%

31.2%

-



2,152


1,765

21.9%

21.9%

-


Intl


504


621

-18.8%

-18.8%

0.0%



1,607


1,986

-19.1%

-18.7%

-0.4%


WW


1,299


1,227

5.9%

5.9%

0.0%



3,759


3,751

0.2%

0.4%

-0.2%


ACIPHEX/PARIET

















US


89


80

11.3%

11.3%

-



289


280

3.2%

3.2%

-


Intl


44


115

-61.7%

-62.0%

0.3%



152


369

-58.8%

-58.7%

-0.1%


WW


133


195

-31.8%

-32.0%

0.2%



441


649

-32.0%

-32.0%

0.0%


PROCRIT/EPREX

















US


204


198

3.0%

3.0%

-



627


634

-1.1%

-1.1%

-


Intl


140


161

-13.0%

-14.4%

1.4%



430


502

-14.3%

-14.9%

0.6%


WW


344


359

-4.2%

-4.8%

0.6%



1,057


1,136

-7.0%

-7.3%

0.3%


XARELTO

















US


246


68

*

*

-



593


144

*

*

-


Intl


-


-

-

-

-



-


-

-

-

-


WW


246


68

*

*

-



593


144

*

*

-


OTHER

















US


256


260

-1.5%

-1.5%

-



643


707

-9.1%

-9.1%

-


Intl


320


345

-7.2%

-6.4%

-0.8%



1,025


1,115

-8.1%

-7.2%

-0.9%


WW


576


605

-4.8%

-4.4%

-0.4%



1,668


1,822

-8.5%

-7.9%

-0.6%



















TOTAL PHARMACEUTICAL

















US


3,549


3,288

7.9%

7.9%

-



10,397


9,408

10.5%

10.5%

-


Intl


3,487


3,114

12.0%

14.0%

-2.0%



10,432


9,418

10.8%

12.9%

-2.1%


WW

$

7,036


6,402

9.9%

10.9%

-1.0%


$

20,829


18,826

10.6%

11.7%

-1.1%





















































See footnotes at end of schedule















 


REPORTED SALES vs. PRIOR PERIOD ($MM)


THIRD QUARTER


NINE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)
















CARDIOVASCULAR CARE
















US

$

196


195

0.5%

0.5%

-


$

598


566

5.7%

5.7%

-

Intl


305


298

2.3%

6.6%

-4.3%



945


913

3.5%

7.5%

-4.0%

WW


501


493

1.6%

4.2%

-2.6%



1,543


1,479

4.3%

6.8%

-2.5%

DIABETES CARE
















US


237


328

-27.7%

-27.7%

-



779


1,017

-23.4%

-23.4%

-

Intl


320


301

6.3%

6.5%

-0.2%



967


955

1.3%

2.2%

-0.9%

WW


557


629

-11.4%

-11.3%

-0.1%



1,746


1,972

-11.5%

-11.0%

-0.5%

DIAGNOSTICS
















US


222


256

-13.3%

-13.3%

-



711


767

-7.3%

-7.3%

-

Intl


237


257

-7.8%

-2.8%

-5.0%



708


772

-8.3%

-4.1%

-4.2%

WW


459


513

-10.5%

-8.0%

-2.5%



1,419


1,539

-7.8%

-5.7%

-2.1%

INFECTION PREVENTION/OTHER
















US


91


98

-7.1%

-7.1%

-



271


313

-13.4%

-13.4%

-

Intl


129


134

-3.7%

4.3%

-8.0%



395


393

0.5%

6.9%

-6.4%

WW


220


232

-5.2%

-0.5%

-4.7%



666


706

-5.7%

-2.1%

-3.6%

ORTHOPAEDICS
















US 


1,232


1,242

-0.8%

-0.8%

-



3,767


2,898

30.0%

30.0%

-

Intl


1,051


1,048

0.3%

3.4%

-3.1%



3,286


2,513

30.8%

34.3%

-3.5%

WW


2,283


2,290

-0.3%

1.1%

-1.4%



7,053


5,411

30.3%

31.9%

-1.6%

SPECIALTY SURGERY
















US


321


308

4.2%

4.2%

-



971


971

0.0%

0.0%

-

Intl


305


289

5.5%

9.2%

-3.7%



938


900

4.2%

7.2%

-3.0%

WW


626


597

4.9%

6.7%

-1.8%



1,909


1,871

2.0%

3.4%

-1.4%

SURGICAL CARE 
















US


587


602

-2.5%

-2.5%

-



1,695


1,797

-5.7%

-5.7%

-

Intl


947


949

-0.2%

3.9%

-4.1%



2,935


3,019

-2.8%

0.6%

-3.4%

WW


1,534


1,551

-1.1%

1.4%

-2.5%



4,630


4,816

-3.9%

-1.8%

-2.1%

VISION CARE
















US


265


260

1.9%

1.9%

-



808


790

2.3%

2.3%

-

Intl


483


504

-4.2%

4.9%

-9.1%



1,410


1,461

-3.5%

4.3%

-7.8%

WW


748


764

-2.1%

3.9%

-6.0%



2,218


2,251

-1.5%

3.6%

-5.1%

















TOTAL MEDICAL DEVICES AND DIAGNOSTICS
















US


3,151


3,289

-4.2%

-4.2%

-



9,600


9,119

5.3%

5.3%

-

Intl


3,777


3,780

-0.1%

4.2%

-4.3%



11,584


10,926

6.0%

10.0%

-4.0%

WW

$

6,928


7,069

-2.0%

0.3%

-2.3%


$

21,184


20,045

5.7%

7.9%

-2.2%

















* Percentage greater than 100%















(1) Operational growth excludes the effect of currency












(2) Select areas (unaudited)















(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals









(4) Prior year amounts have been reclassified to conform to current year product disclosure









(5) Reported as U.S. sales















SOURCE Johnson & Johnson

News Provided by Acquire Media


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.